Thomas Diraimondo net worth and biography

Thomas Diraimondo Biography and Net Worth

Insider of Janux Therapeutics

Tommy joined the Janux Therapeutics team in May 2018 and currently serves as Chief Scientific Officer. He manages the internal and external research operations and has been an integral part in the creation and reduction to practice of key technologies protected by the ever-growing Janux intellectual property portfolio. Before Janux, Tommy was the co-founder of Sitari Pharmaceuticals based upon his graduate work at Stanford University with Professor Chaitan Khosla. Tommy was a key leader in the Sitari drug discovery and development program, whose successful culmination was the acquisition by GlaxoSmithKline.

Tommy earned his Ph.D. in Chemical Engineering from Stanford University, his M.S.E. in Pharmaceutical Engineering, and his B.S.E in Chemical Engineering from the University of Michigan, Ann Arbor.

What is Thomas Diraimondo's net worth?: The estimated net worth of Thomas Diraimondo is at least $1.68 million as of January 2nd, 2026. Diraimondo owns 124,425 shares of Janux Therapeutics stock worth more than $1,679,738 as of February 18th. This net worth approximation does not reflect any other investments that Diraimondo may own. Learn More about Thomas Diraimondo's net worth.
How do I contact Thomas Diraimondo?: The corporate mailing address for Diraimondo and other Janux Therapeutics executives is , , . Janux Therapeutics can also be reached via phone at 858-751-4493 and via email at [email protected]. Learn More on Thomas Diraimondo's contact information.
Has Thomas Diraimondo been buying or selling shares of Janux Therapeutics?: Over the course of the past ninety days, Thomas Diraimondo has sold $34,393.65 in Janux Therapeutics stock. Most recently, Thomas Diraimondo sold 2,505 shares of the business's stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $13.73, for a transaction totalling $34,393.65. Following the completion of the sale, the insider now directly owns 124,425 shares of the company's stock, valued at $1,708,355.25. Learn More on Thomas Diraimondo's trading history.
Who are Janux Therapeutics' active insiders?: Janux Therapeutics' insider roster includes David Campbell (Founder, President & CEO), Thomas Diraimondo (Insider), Maria Dobek (VP), Zachariah Mciver (Insider), Andrew Meyer (Chief Business Officer), and Charles Winter (Insider). Learn More on Janux Therapeutics' active insiders.
Are insiders buying or selling shares of Janux Therapeutics?: During the last year, Janux Therapeutics insiders bought shares 2 times. They purchased a total of 451,948 shares worth more than $13,889,565.00. During the last year, insiders at the sold shares 12 times. They sold a total of 52,365 shares worth more than $1,286,149.42. The most recent insider tranaction occured on January, 2nd when insider Thomas Diraimondo sold 2,505 shares worth more than $34,393.65. Insiders at Janux Therapeutics own 29.4% of the company. Learn More about insider trades at Janux Therapeutics.
Information on this page was last updated on 1/2/2026.

Thomas Diraimondo Insider Trading History at Janux Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/2/2026	Sell	2,505	$13.73	$34,393.65	124,425

Thomas Diraimondo Buying and Selling Activity at Janux Therapeutics

Janux Therapeutics Company Overview

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Today's Range

Now: $13.50

$13.16

$13.53

50 Day Range

MA: $13.93

$12.18

$15.58

2 Week Range

Now: $13.50

$12.12

$38.42

Volume

221,964 shs

Average Volume

1,539,475 shs

Market Capitalization

$812.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.88